Since the tumor was PD‐L1 positive (tumor proportion score 99% on immunohistochemical staining with the PD‐L1 SP263 clone), he was then put on an immunotherapy regimen with an immune checkpoint inhibitor (durvalumab) once every 4 weeks for a year. This evidence concerns the gene CD274 and neoplasm.